Infliximab Prevents Bone Loss in Rheumatoid Arthritis Patients
Author Information
Author(s): Marotte Hubert, Pallot-Prades Beatrice, Grange Laurent, Gaudin Philippe, Alexandre Christian, Miossec Pierre
Primary Institution: Hospices Civils de Lyon
Hypothesis
Does infliximab treatment prevent loss of bone mineral density in patients with rheumatoid arthritis?
Conclusion
Infliximab therapy prevents bone loss in rheumatoid arthritis patients, even in those who do not respond clinically.
Supporting Evidence
- Bone mineral density decreased in the control group but remained stable in the infliximab group.
- Infliximab treatment showed no significant change in bone turnover markers over one year.
- 64% of infliximab patients were classified as good responders based on clinical improvement.
Takeaway
This study shows that a medicine called infliximab helps keep bones strong in people with rheumatoid arthritis, even if they don't feel better.
Methodology
A case-control study comparing bone mineral density changes in RA patients treated with infliximab versus a historical control group treated with methotrexate.
Potential Biases
Potential bias due to the non-randomized design and reliance on historical controls.
Limitations
The study used historical controls, which may not fully account for all confounding factors.
Participant Demographics
The study included 189 RA patients, with 152 women and 37 men, average age 52.5 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website